Board of Directors

Leon Chen

OrbiMed

Carol Gallagher

NEA

Steven P. James

President and CEO, Pionyr Immunotherapeutics

Max Krummel, PhD

Robert E. Smith Endowed Chair in Experimental Pathology, UCSF

Mike Powell

Sofinnova

Mike Ross, PhD

SV Health Investors


Leon Chen

OrbiMed

Leon Chen, Ph.D., is a Venture Partner with OrbiMed. Prior to joining OrbiMed, Dr. Chen was the co-founder of KAI Pharmaceuticals where he built the company as the first employee. He held responsibilities in research, intellectual property and business development before Amgen acquired KAI in 2012. He was previously an Entrepreneur in Residence at Venrock and most recently was a Partner at Skyline Ventures where he served on the board of a number of biotech and diagnostic companies. Dr. Chen has a B.A. in Biochemistry from U.C. Berkeley, a Ph.D in Molecular Pharmacology from Stanford and an M.B.A from the Stanford Graduate School of Business.

Carol Gallagher

NEA

Dr. Gallagher joined NEA as a Partner in October, 2014. She is a proven entrepreneur, operator and, more recently, investor with nearly 30 years of experience in commercial, drug development and business development roles at large and small pharmaceutical companies. From 2008-2011, Dr. Gallagher was president and CEO of Calistoga Pharmaceuticals which developed the first-in-class therapeutic now marketed by Gilead as ZYDELIG. After the sale of Calistoga Pharmaceuticals, she spent several years serving as an independent director on multiple biopharma company boards before pursuing a career in venture capital. In addition to serving as a director at Pionyr, she currently serves as Chairman of the Board at Millendo Therapeutics, lead director at Atara Bio, and as a director at Metacrine, Cleave Biosciences and AnaptysBio.

Steven P. James

President and CEO, Pionyr Immunotherapeutics

Steve has over 25 years of biopharma experience and has been involved in building and leading numerous companies. Prior to joining Pionyr in February 2016, he was president, CEO, and a director of Labrys Biologics until it was acquired by Teva Pharmaceuticals. Prior to Labrys, Steve was president, CEO, and a director of KAI Pharmaceuticals which was acquired by Amgen. He has held leadership positions at Exelixis, Sunesis Pharmaceuticals, Ionis Pharmaceuticals, and Eli Lilly. He holds a Masters in Management from the Kellogg School of Northwestern University and an undergraduate degree in neuroscience from Brown University. Steve was formerly a director of Ocera Inc. (acquired by Mallinkrodt) and Cascadian Therapeutics (acquired by Seattle Genetics) and is currently chairman of Antiva Biosciences and a director of Allakos Inc., and Chrono Therapeutics. He is also a trustee of Middlebridge School in Rhode Island.

Max Krummel, PhD

Robert E. Smith Endowed Chair in Experimental Pathology, UCSF

Dr. Krummel is a Professor and the Robert E. Smith Endowed Chair in Experimental Pathology at UCSF. He studies mechanisms that regulate T cell response and immune function, using cutting-edge real-time imaging methods. As a graduate student, he developed expertise in the generation and use of monoclonal antibodies targeted to costimulatory and inhibitory molecules on T cells. He generated antibodies to CTLA-4, which identified an inhibitory pathway of T cell regulation and also could be used to trigger or block that pathway. This approach led to the development of human antibodies of the same type, a therapy now named ‘ipilimumab’, now FDA approved and widely used for treatment of melanoma and other cancers.

Dr. Krummel’s lab now focuses on figuring out how immune systems, collections of cells in complex tissues, work. The use of fluorescent proteins and real-time imaging enable the examination of information processing by the immune system. These approaches reveal how motile immune cells ‘search’ their environment for critical information and characterize specific phagocytes in the tumor microenvironments as primary players in transmitting signals to lymphocytes and regulating disease outcome.

Dr. Krummel earned his doctorate at UC Berkeley and did postdoctoral fellowships at Stanford University and the Walter and Eliza Hall Institute in Melbourne, Australia.

Mike Powell

Sofinnova

Mike joined Sofinnova as a General Partner in 1997. He represents Sofinnova as the Chairman of Galera Therapeutics, Checkmate Pharma, and Dauntless Pharmaceuticals. Prior investments include Labrys Biologics (acquired by Teva) and Intellikine (acquired by Millennium/Takeda). Mike was the initial investor in Actelion (ATLN), InterMune (ITMN), Orexigen Therapeutics (OREX), Seattle Genetics (SGEN), Threshold Pharmaceuticals (THLD), and Trius Therapeutics (TSRX). Before joining Sofinnova, Mike was Group Leader of Drug Delivery at Genentech (1990–97) where his focus was developing new formulations for protein and peptide therapeutics. Mike was the first scientist from the biotechnology industry to be honored as a Fellow of the American Association of Pharmaceutical Scientists.

Mike received his PhD in Physical Chemistry from the University of Toronto and completed his post-doctorate work in Bioorganic Chemistry at the University of California, where he was subsequently a faculty member (1981–84). He currently serves on the Washington University Board of Trustees in St. Louis. He is also an Adjunct Professor of Pharmaceutical Chemistry at the University of Kansas, and past Editorial Board member of J. Pharm. Sci., and a past Scientific Advisor to the Controlled Release Society.

Mike Ross, PhD

SV Health Investors

Mike Ross’ career spans over 15 years in venture capital, which followed 21 years in senior operating executive roles for leading biotechnology companies. He joined SV Health Investors as a Venture Partner in 2001 and became a Managing Partner in 2002. Mike was the tenth employee at Genentech, where he worked for 13 years. He served as Genentech team leader for the Humulin® Roferon®, Protropin® programs and was Vice President of Development during the development of Activase®, Nutropin® and Pulmozyme®. He then started Genentech’s protein engineering and small molecule discovery effort as Vice President of Medicinal and Biomolecular Chemistry. Mike was the Founding CEO of Arris Pharmaceutical, MetaXen, ExSAR and CyThera (now Viacyte). He was also Managing Partner in Didyma, LLC, a biotechnology management consulting firm. Mike served on the boards of Carta Proteomics, Epimmune, Genencor, MetaXen, and Xenova.

Mike received his PhD in Chemistry from Caltech and went on to do his post-doctoral work at Harvard. He serves on the Board of the Thayer School of Engineering (Dartmouth College).